| 1 |
34851444 | Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers. | 2022 Jan |
1 |
| 2 |
35165925 | Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. | 2022 Feb 15 |
1 |
| 3 |
35238961 | Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. | 2022 Jun |
1 |
| 4 |
32691891 | Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants. | 2021 Jan |
2 |
| 5 |
33826998 | Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. | 2021 Jun |
3 |
| 6 |
31673875 | Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study. | 2020 Feb |
1 |
| 7 |
30301385 | Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. | 2019 Aug |
1 |
| 8 |
30676743 | Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules. | 2019 Feb 19 |
2 |
| 9 |
30912163 | Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. | 2019 Jul |
3 |
| 10 |
31090092 | Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. | 2019 Nov |
2 |
| 11 |
31145690 | Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. | 2019 May 30 |
1 |
| 12 |
31475367 | Population pharmacokinetics of sildenafil in extremely premature infants. | 2019 Dec |
1 |
| 13 |
28249055 | Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx? | 2017 Mar |
1 |
| 14 |
27430348 | Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review. | 2016 Oct |
2 |
| 15 |
25670523 | Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. | 2015 Feb |
1 |
| 16 |
26471025 | [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. | 2015 Oct 5 |
1 |
| 17 |
25429674 | Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. | 2014 |
4 |
| 18 |
27128233 | Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. | 2014 Jan |
1 |
| 19 |
23462027 | Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout. | 2013 Mar |
1 |
| 20 |
22048224 | Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. | 2012 Mar |
2 |
| 21 |
21545485 | Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. | 2011 Aug |
2 |
| 22 |
21712512 | Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. | 2011 Jul |
1 |
| 23 |
24451503 | [Interaction between azole antifugals drugs and tacrolimus in four kidney transplant patients]. | 2011 Mar |
1 |
| 24 |
19889796 | Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist. | 2010 Feb |
1 |
| 25 |
20175801 | Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers. | 2009 Dec |
2 |
| 26 |
17954524 | The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. | 2008 Jan |
1 |
| 27 |
18381488 | Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. | 2008 Jul |
1 |
| 28 |
18812562 | Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. | 2008 Nov |
1 |
| 29 |
16556082 | Drug interactions during therapy with three major groups of antimicrobial agents. | 2006 Apr |
1 |
| 30 |
15843491 | Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. | 2005 Jul |
1 |
| 31 |
15963096 | The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. | 2005 Jul |
1 |
| 32 |
16205037 | [Drug-drug interaction of antifungal drugs]. | 2005 Oct |
4 |
| 33 |
12949438 | Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. | 2003 |
1 |
| 34 |
11932962 | Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. | 2002 Mar |
1 |
| 35 |
12405865 | Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. | 2002 |
1 |
| 36 |
10709776 | Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. | 2000 Feb |
2 |
| 37 |
10923859 | Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. | 2000 Jun |
1 |
| 38 |
10926350 | Drug interactions with cisapride: clinical implications. | 2000 Jul |
1 |
| 39 |
9929500 | Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. | 1999 Feb |
2 |
| 40 |
10341997 | Interaction between fluconazole and midazolam in intensive care patients. | 1999 May |
1 |
| 41 |
10456482 | Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions. | 1999 Jul |
1 |
| 42 |
10466905 | Potential fluconazole-induced carbamazepine toxicity. | 1999 Jul-Aug |
2 |
| 43 |
10730911 | Drug interactions of the newer oral antifungal agents. | 1999 Nov |
1 |
| 44 |
8520811 | 150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects. | 1995 Sep |
1 |